Advertisement

You will be redirected to the page you want to view in  seconds.

THOUSAND OAKS, Calif. (AP) - Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test.

The results, released late Tuesday, show there's promise for similar vaccines other companies are developing.

The experimental injected drug made tumors shrink for six months in 16% of study participants. That compares with tumor shrinkage in just 2% of patients in a control group that received a standard treatment.

Amgen also says its interim analysis indicates the drug, dubbed T-VEC for short, may help patients survive longer. More definitive data are expected soon.

Shares of Thousand Oaks, Calif.-based Amgen rose $1.92, or 2.1%, to $94.32 in early afternoon trading.



Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Read the original story: Virus vaccine shrinks melanoma tumors

More In

test

Real Deals

Flip, shop and save on specials from your favorite retailers in central Ohio.

GET DEALS | COUPONS

Things To Do

MON
22
TUE
23
WED
24
THU
25
FRI
26
SAT
27
SUN
28

CLASSIFIEDS

Classifieds from across Central Ohio
Lancaster
Chillicothe
Newark
Marion
Bucyrus
Mansfield
Zanesville
Coshocton

Weeklies & Shoppers

10TV Headlines

Dispatch Headlines

METROMIX